GSK announces phase III clinical study targeting cancer drug Zejula for patients with advanced ovarian cancer reaches major end point

GlaxoSmithKline (GSK), the uk'spharmaceutical(http://, recently announced that the evaluation of the targeted anti-cancer drug Zejula (Chinese brand name: Seile, generic name: niraparib, Nirapani) first-line maintenance treatment of patients with advanced ovarian cancer phase III clinical research PRIMA (ENGOT-OV26/GOG-3012) reached the main endThis is a randomized, double-blind, placebo-controlled study designed to assess the efficacy of Zejula and placebos in patients with stage III or STAGE IV ovarian cancerThe study assessed the efficacy of Zejula as a maintenance treatmentdrug(http://, measured by progressionless life (PFS)In the study, patients were randomly assigned a 2:1 ratio after receiving platinum-containing chemotherapy and received Zejula or placebo-based first-line maintenance therapyThe results showed that the study reached a major endpoint: for first-line maintenance therapy, the Zejula treatment group achieved a statistically significant improvement in PFS compared to the placebo group, regardless of the patient's biomarker statusIn this study, Zejula's safety and tolerance were consistent with previous clinical studiesAbout Zejula
Zejula is an oral, small-molecule polypolymer anucleocopolymerase (PARP) inhibitor that uses defects in DNA repair pathways to kill cancer cells first, a mode of action that gives the drug the potential to treat a wide range of tumors with DNA repair defectsPARP is associated with a wide range of tumor types, especially breast and ovarian cancer 　　Zejula is a potentially best-of-breed PARP inhibitor due to its differentiated efficacy, daily dose and superior pharmacokinetic features, including its ability to cross the blood-brain barrier 　　In addition to ovarian cancer, Zejula is currently being evaluated as a combination of therapy for lung, breast and prostate cancer